Voyager Therapeutics has appointed Robin Swartz, the company's Chief Business Officer and Chief Operating Officer, to the role of President, effective October 20, 2026. The company also announced a CEO succession plan where Ms. Swartz is expected to succeed Dr. Alfred W. Sandrock, Jr. as Chief Executive Officer in the first quarter of 2027.
Key Details
- Appointment & Succession: Robin Swartz was appointed President, effective immediately. She is expected to become CEO in Q1 2027, succeeding Alfred W. Sandrock, Jr., who will remain on the Board of Directors.
- CEO Transition Trigger: The CEO transition is contingent upon receiving initial acute safety data from its clinical trial of VY1706 for early Alzheimer’s Disease.
- New Compensation: In connection with her appointment, Ms. Swartz's amended employment agreement includes an annual base salary of $625,000, a target bonus of 50%, a stock option to purchase 318,500 shares, and a restricted stock unit (RSU) award for 68,250 shares.